MHRA starts rolling reviews of AstraZeneca’s COVID-19 vaccine candidate
Category: #headlines  By Nikita Chaurasia  Date: 2020-11-02
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

MHRA starts rolling reviews of AstraZeneca’s COVID-19 vaccine candidate

British multinational pharmaceutical company AstraZeneca Plc has reportedly announced that the Medicines & Healthcare Products Regulatory Agency (MHRA) has begun an accelerated rolling review of its potential COVID-19 vaccine.

Typically, health regulators can observe clinical evidence in real time during rolling reviews and subsequently converse with drug manufacturers regarding the production processes as well as trials in order to speed up the approval process. The approach is designed to boost testing, especially during a public health emergency of promising vaccines.

For those uninitiated, AstraZeneca has partnered with University of Oxford for the development of coronavirus vaccine. The work on the potential COVID-19 vaccine called ChAdOx1 nCoV-19 or AZD1222 had started in the month of January 2020. Reportedly, the viral vector of the vaccine is produced from a weakened variant of a common cold virus.

The British drug marker claimed that its experimental vaccine can induce an immune response among both young adults and old individuals. Evidently, the vaccine also induces decreased adverse reactions among the elderly.

Currently, the leaders in the competition to produce a coronavirus vaccine are Pfizer Inc., AstraZeneca, Moderna Inc. as well as Johnson & Johnson. Reportedly, MHRA has also initiated an accelerated analysis of Pfizer's coronavirus vaccine candidate.

The vaccine contenders are currently in late-stage research, with interim results anticipated in the upcoming weeks, cited sources with relevant information.

It is to be noted that over 46.5 million people across the globe have been affected by the coronavirus, with recovery rates recording at 31.1 million and mortality numbers surpassing 1.2 million.

Meanwhile, Australia is expected to start manufacturing AstraZeneca and Oxford’s COVID-19 vaccine by late November, with doctors and elderly having access to the treatment by March 2021, sources claimed.

Source credits –

https://www.reuters.com/article/uk-health-coronavirus-astrazeneca-vaccin-idUSKBN27H1BD

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

3D-model platform Sketchfab becomes Epic Games’ next big acquisition

3D-model platform Sketchfab becomes Epic Games’ next big acquisition

By Nikita Chaurasia

After RAD Game Tools and Quixel Megascans, American video game and software development company Epic Games Inc. has now acquired Sketchfab, the platform that boasts of over 4 million 3D models where artists can publish, modify, and sell their creatio...

Flipkart app now has a 3D camera for an immersive AR e-comm experience

Flipkart app now has a 3D camera for an immersive AR e-comm experience

By Nikita Chaurasia

Indian e-commerce giant Flipkart has introduced an Augmented Reality (AR) infused e-commerce experience with Flipkart Camera that would allow shoppers a real-life experience before purchasing a product. The novel feature built in the app should help ...

SPAC Stonebridge Acquisition raises USD 200 million during U.S. IPO

SPAC Stonebridge Acquisition raises USD 200 million during U.S. IPO

By Nikita Chaurasia

The India-focused SPAC intends to reach its target within 12-16 months. The fresh funds will be used to acquire Indian businesses valued between USD 1-1.5 billion. Texas-based special purpose acquisition company (SPAC) Stonebridge Acquisition Co...